SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-040668
Filing Date
2023-02-16
Accepted
2023-02-16 06:45:34
Documents
14
Period of Report
2023-02-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d455825d8k.htm   iXBRL 8-K 25131
2 EX-99.1 d455825dex991.htm EX-99.1 85696
6 GRAPHIC g455825g0215212406459.jpg GRAPHIC 1859
  Complete submission text file 0001193125-23-040668.txt   248513

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20230216.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20230216_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20230216_pre.xml EX-101.PRE 10810
8 EXTRACTED XBRL INSTANCE DOCUMENT d455825d8k_htm.xml XML 3291
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 23637065
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences